CD19CAR-CD28-CD3zeta-EGFRt

CD19CAR-CD28-CD3zeta-EGFRt is a preparation of genetically modified autologous human T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the B-cell surface antigen CD19. The CAR construct includes an extracellular anti-CD19 single-chain variable fragment (scFv), a co-stimulatory domain from CD28, and an intracellular signaling domain from CD3-zeta. Additionally, the cells are engineered to express EGFRt (a truncated form of epidermal growth factor receptor) as a safety switch or selection marker. These CAR-T cells are typically enriched for central memory (Tcm) or naïve/memory (Tn/mem) phenotypes to enhance persistence and efficacy. The primary mechanism involves recognition and binding of the CAR to CD19 on malignant B-cells, leading to activation, proliferation, cytokine release, and cytotoxic killing of target cells in a major histocompatibility complex–independent manner. This therapy is under investigation primarily for relapsed/refractory B-cell malignancies such as primary central nervous system lymphoma[1][2][3][5].

Other names

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytesCD-19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytesCD 19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytesCD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes